Alan Wright, CMO of Roche Diagnostics, to Keynote at Biomarkers Summit 2016

San Diego, CA, February 18, 2016 --(PR.com)-- Alan Wright, Chief Medical Officer of Roche Diagnostics, will give a keynote presentation on “Creating Personalized Diagnostics Ecosystems” at GTCbio’s Biomarkers Summit 2016 to be held on March 21-23, 2016 in San Diego, CA.

With a heavy national focus on the bottom line of healthcare, the “what” and “how” of changing paradigms in care can get lost in the shuffle. But the new cornerstone of outcome-based care will increasingly become companion diagnostics. Personalized healthcare has evolved into predictive, precision therapeutics that improve bottom line financials while delivering better patient care. Will improved medical care be informed by FDA-approved wearable devices? How can recreation-only diagnostics improve in quality to monitor physical attributes like gait and blood pressure and inform medical decision making? Will smart phones continue to grow in capabilities and global uptake to become a convergence point for personal laboratory information? We are at the confluence of central lab, point of care, and wearable diagnostics, creating the ideal environment for personalized diagnostics ecosystems.

This summit will discuss issues and challenges scientists and researchers face in all aspects of the biomarker and diagnostic development process from discovery to translation to commercialization. Assembling leading scientists, researchers, decision-makers and other players across the industry spectrum, the Summit provides a unique opportunity to gain the latest biomarker developments in three major therapeutic areas, formally organized in the following tracks:

General Session:
I. Plenary Keynote Session
II. Big Data Analytics for Biomarker Development
III. Novel Technologies in Biomarker Development
IV. Panel Discussion: Companion Diagnostics Development & Partnering Strategies
V. Panel Discussion: Non-profits Perspectives on Precision Medicine
VI. Overcoming Challenges of Clinical Validation & Translation
VII. Panel Discussion: Regulatory & Reimbursement Trends in Biomarker Development

9th Oncology Biomarkers
I. Minimally Invasive & Non-invasive Approaches in Cancer
II. Emerging Discovery Pipelines
III. Immuno-Oncology Biomarker Discovery (Joint Session)

5th Neurological Biomarkers
I. Developments in Neurological & Neurodegenerative Disorders
II. CSF & Blood Based Biomarker Approaches
III. Imaging Approaches in CNS Drug Discovery & Development

5th Inflammatory & Immunological Biomarkers
I. Biomarkers of Early Progressive Inflammatory & Immunological Diseases
II. Biomarkers & Surrogate Endpoints for Clinical Trials in Inflammatory Diseases
III. Novel Approaches to Immunological Biomarkers
IV. Immuno-Oncology Biomarker Discovery (Joint Session)

For more information, please visit the website: www.gtcbio.com/biomarkers

GTCbio
635 W. Foothill Blvd
Monrovia, CA 91016
www.gtcbio.com/
Email: infogtcbio@gtcbio.com
Phone: (626) 256-6405
Fax: (626) 466-4433